INKT MiNK Therapeutics, Inc.

Nasdaq minktherapeutics.com


$ 14.21 $ 0.06 (0.43 %)    

Tuesday, 14-Oct-2025 17:46:43 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 14.15
$ 13.82
$ 13.61 x 3
$ 14.75 x 20
$ 13.92 - $ 14.27
$ 4.56 - $ 76.00
59,156
na
64M
$ 2.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-29-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-upgrades-mink-therapeutics-to-buy-maintains-price-target-to-35

HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the ...

 mink-therapeutics-q2-eps-106-misses-046-estimate

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $...

 hc-wainwright--co-downgrades-mink-therapeutics-to-neutral-maintains-price-target-to-35

HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains th...

 mink-therapeutics-highlights-inkt-cell-therapy-potential-in-peer-reviewed-article-titled-car-inkt-cells-redefining-the-frontiers-of-cellular-immunotherapy-underscoring-the-power-of-car-inkt-as-next-gen-solid-tumor-treatment

MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...

 william-blair-downgrades-mink-therapeutics-to-market-perform

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:INKT) from Outperform to Market Perform.

 why-is-nano-cap-mink-therapeutics-stock-gaining-over-400-on-friday

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION